NEURONETICS INC (STIM) 6.2 -0.04 (-0.64%)
6.2 -0.04 (-0.64%)
US64131A1051 - Common Stock
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing,...
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
NeuroStar’s technology once again recognized as an effective non-drug treatment for patients...
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
NeuroStar’s technology once again recognized as an effective non-drug treatment for patients
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing,...
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy...
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing,...
Neuronetics Reports Third Quarter 2022 Financial and Operating Results
MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision...
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health...
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS...
Neuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing,...
Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need...
Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony
The state-of-the-art training center is the first of its kind to further best practices with transformative NeuroStar Advanced Therapy for Mental Health...
Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health
Latest NeuroStar innovation to simplify the motor threshold determination for clinicians...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing,...
Neuronetics Reports Second Quarter 2022 Financial and Operating Results
MALVERN, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision...
Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference
MALVERN, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing,...